- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07595016
Clinical Validation of the Blood Pressure Measuring Device Withings BPM Pro 2 in Pregnancy and Pre-Eclampsia (WIHYP-PW)
June 1, 2026 updated by: Withings
Clinical Validation Of The Brachial Blood Pressure Measuring Device Withings BPM Pro 2 According To "The Universal Protocol For The Validation Of Blood Pressure Measuring Devices By The Association For The Advancement Of Medical Instrumentation / European Society Of Hypertension / International Organization For Standardization (AAMI/ESH/ISO) (And Its Amendment 1 (2020) And 2 (2024))" In Pregnancy And Pre-Eclampsia
The aim of the study is to assess the accuracy of the automatic oscillometric BP measuring device at the brachial level, the WITHINGS BPM Pro 2, in pregnancy and pre-eclampsia
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Inès Bedouda
- Phone Number: 0141460460
- Email: clinical-trials@withings.com
Study Locations
-
-
Armenia
-
Yerevan, Armenia, Armenia, 0002
- Recruiting
- N2
-
Contact:
- Parounak ZELVEIAN, Professor
- Phone Number: 374-10-530572
- Email: zelveian@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patient older than 18 years;
- Known pregnancy, in second or third trimester of pregnancy ( > 3 months);
- Patient normotensive, hypertensive or in preeclampsia;
- Patient who signed the informed consent form;
- Patient followed-up at site (in-patient or out-patient);
- Patient with arm circumference between 22 cm and 42 cm.
Exclusion Criteria:
- Patient unable to give a consent or understand properly protocol information;
- Patient suffering from arrhythmia;
- Patient with poor quality of Korotkov sounds;
- Patient for whom K5 sounds are absent;
- Patient wearing an implantable electric medical device (pacemaker,…);
- Patient with both upper arms suffering from open wound and/or damaged skin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: All patients
Patients consenting to participate to the study and compliant to the inclusion criteria
|
The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood pressure measurement performace evaluation per measure
Time Frame: 5 months
|
The blood pressure (systolic and diastolic blood pressure) measurement performance will be established using the mean value of the differences and the standard deviation between the device under study and the reference for each measure.
|
5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2026
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
May 12, 2026
First Submitted That Met QC Criteria
May 12, 2026
First Posted (Actual)
May 19, 2026
Study Record Updates
Last Update Posted (Actual)
June 3, 2026
Last Update Submitted That Met QC Criteria
June 1, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Pre-Eclampsia
- Hypertension
- Diagnostic Techniques and Procedures
- Diagnosis
- Diagnostic Techniques, Cardiovascular
- Physical Examination
- Blood Pressure Determination
Other Study ID Numbers
- 2026-A00642-49
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on Blood pressure measurement
-
Kaiser PermanentePatient-Centered Outcomes Research InstituteCompleted
-
Renaissance University Ugbawka, EnuguEnrolling by invitation
-
Summit Doppler Systems, Inc.The Cleveland ClinicCompletedPeripheral Arterial DiseaseUnited States
-
Hospital Clinic of BarcelonaRecruitingArterial Hypertension | Frailty Syndrome | Heart Failure With Preserved Ejection Fraction | Comorbidities and Coexisting ConditionsSpain
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Albany Medical CollegeCompleted
-
BiospectalCSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et...UnknownBlood PressureSwitzerland
-
Summit Doppler Systems, Inc.The Cleveland ClinicCompletedPeripheral Arterial DiseaseUnited States